Information Provided By: 
Fly News Breaks for June 17, 2019
JAZZ
Jun 17, 2019 | 10:39 EDT
Jazz Pharmaceuticals this morning announced that the U.S. Drug Enforcement Agency has given Sunosi, formerly known as JZP110, a Schedule IV medicine designation, Wells Fargo analyst David Maris tells investors in a research note. The analyst, who points out Provigil is also a Schedule IV drug, believes this outcome is a positive for Jazz and Sunosi. Maris models Sunosi sales of $12M in 2019 and approximately $180M in sales by 2021. He keeps an Outperform rating on shares of Jazz Pharmaceuticals.
News For JAZZ From the Last 2 Days
There are no results for your query JAZZ
